US6140466A
(en)
|
1994-01-18 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
US20050084885A1
(en)
*
|
1994-01-18 |
2005-04-21 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
US7070934B2
(en)
*
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US6599692B1
(en)
*
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
US7329728B1
(en)
*
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
IL150069A0
(en)
*
|
1999-12-06 |
2002-12-01 |
Sangamo Biosciences Inc |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
GB0015090D0
(en)
*
|
2000-06-20 |
2000-08-09 |
Implyx Ltd |
Gene-activating conjugates
|
US7026462B2
(en)
*
|
2000-12-07 |
2006-04-11 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
WO2002057294A2
(en)
*
|
2001-01-22 |
2002-07-25 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for dna binding and gene regulation in plants
|
US7067617B2
(en)
*
|
2001-02-21 |
2006-06-27 |
The Scripps Research Institute |
Zinc finger binding domains for nucleotide sequence ANN
|
US20050235369A1
(en)
*
|
2001-03-28 |
2005-10-20 |
Yen Choo |
Gene regulation II
|
US20040224385A1
(en)
*
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
EP1451297A4
(en)
|
2001-12-07 |
2006-06-28 |
Toolgen Inc |
Phenotypic screen of chimeric proteins
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
AU2003251286B2
(en)
|
2002-01-23 |
2007-08-16 |
The University Of Utah Research Foundation |
Targeted chromosomal mutagenesis using zinc finger nucleases
|
WO2004018632A2
(en)
*
|
2002-08-23 |
2004-03-04 |
Sangamo Biosciences, Inc. |
High-throughput screen for modulators of chromatin modifying activity
|
US7361635B2
(en)
|
2002-08-29 |
2008-04-22 |
Sangamo Biosciences, Inc. |
Simultaneous modulation of multiple genes
|
US9447434B2
(en)
|
2002-09-05 |
2016-09-20 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
AU2003304087A1
(en)
*
|
2002-10-23 |
2004-11-26 |
The General Hospital Corporation |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
EP1579005A4
(en)
*
|
2002-11-15 |
2007-07-25 |
Sangamo Biosciences Inc |
Methods and compositions for analysis of regulatory sequences
|
CA2508631A1
(en)
*
|
2002-12-09 |
2004-06-24 |
Toolgen, Inc. |
Regulatory zinc finger proteins
|
DE602004030272D1
(en)
*
|
2003-07-31 |
2011-01-05 |
Kao Corp |
POWDERY COMPOSITION FOR PAPER MANUFACTURE
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20080131962A1
(en)
|
2006-05-25 |
2008-06-05 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
US20090312277A1
(en)
*
|
2004-11-19 |
2009-12-17 |
Abdelhadi Rebbaa |
Compositions And Methods For Reversing Or Preventing Resistance Of A Cancer Cell To A Cytotoxic Agent
|
CA2631422A1
(en)
*
|
2005-11-28 |
2007-05-31 |
The Scripps Research Institute |
Zinc finger binding domains for tnn
|
US20070154989A1
(en)
*
|
2006-01-03 |
2007-07-05 |
The Scripps Research Institute |
Zinc finger domains specifically binding agc
|
WO2007106603A2
(en)
*
|
2006-01-06 |
2007-09-20 |
The Scripps Research Institute |
Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
|
EP1993586A4
(en)
*
|
2006-02-09 |
2009-10-21 |
Sangamo Biosciences Inc |
Method for treating peripheral arterial disease with zinc finger proteins
|
JP2009537140A
(en)
*
|
2006-05-19 |
2009-10-29 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Methods and compositions for inactivation of dihydrofolate reductase
|
WO2007139982A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
US8148129B2
(en)
*
|
2006-06-30 |
2012-04-03 |
The Regents Of The University Of California |
Generation of potent dominant negative transcriptional inhibitors
|
CN101883850B
(en)
*
|
2007-07-12 |
2014-11-12 |
桑格摩生物科学股份有限公司 |
Methods and compositions for inactivating alpha-1,6 fucosyltransferase (FUT 8) gene expression
|
CN101878307B
(en)
*
|
2007-09-27 |
2017-07-28 |
陶氏益农公司 |
Using sour 3 phosphate synthase genes of 5 enolpyrul-shikimates as the engineered zinc finger of target
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
EP2188384B1
(en)
*
|
2007-09-27 |
2015-07-15 |
Sangamo BioSciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
JP2011500082A
(en)
|
2007-10-25 |
2011-01-06 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Methods and compositions for targeted integration
|
JP5763530B2
(en)
|
2008-06-10 |
2015-08-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Methods and compositions for the generation of Bax- and Bak-deficient cell lines
|
KR20160015400A
(en)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
CA2741119C
(en)
|
2008-10-29 |
2019-02-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
CA2745031C
(en)
|
2008-12-04 |
2018-08-14 |
Sangamo Biosciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
CA2749965C
(en)
|
2009-02-04 |
2018-09-11 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
EP2408921B1
(en)
|
2009-03-20 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
EP2419511B1
(en)
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
EP2461819A4
(en)
|
2009-07-28 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for treating trinucleotide repeat disorders
|
NZ619018A
(en)
*
|
2009-10-22 |
2014-06-27 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
GEP20176628B
(en)
|
2010-01-22 |
2017-02-27 |
Sangamo Biosciences Inc |
Targeted genomic alteration
|
JP6137596B2
(en)
|
2010-02-08 |
2017-05-31 |
サンガモ セラピューティクス, インコーポレイテッド |
Engineered truncated half-domain
|
US9255259B2
(en)
*
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
CN102939377B
(en)
|
2010-04-26 |
2016-06-08 |
桑格摩生物科学股份有限公司 |
Use Zinc finger nuclease to carry out genome editor to Rosa site
|
LT2566972T
(en)
|
2010-05-03 |
2020-03-10 |
Sangamo Therapeutics, Inc. |
Compositions for linking zinc finger modules
|
CN103025344B
(en)
|
2010-05-17 |
2016-06-29 |
桑格摩生物科学股份有限公司 |
Novel DNA-associated proteins and application thereof
|
US8945868B2
(en)
|
2010-07-21 |
2015-02-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a HLA locus
|
EP3511420B1
(en)
|
2010-09-27 |
2021-04-07 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
AU2011316575B2
(en)
|
2010-10-12 |
2015-10-29 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia B
|
US9267123B2
(en)
|
2011-01-05 |
2016-02-23 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
AU2012284365B2
(en)
|
2011-07-15 |
2017-04-20 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
JP6261500B2
(en)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Evaluation and improvement of nuclease cleavage specificity
|
CA2841541C
(en)
|
2011-07-25 |
2019-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
CN103917644A
(en)
|
2011-09-21 |
2014-07-09 |
桑格摩生物科学股份有限公司 |
Methods and compositions for regulation of transgene expression
|
AU2012328682B2
(en)
|
2011-10-27 |
2017-09-21 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of the HPRT locus
|
EP2780460B1
(en)
|
2011-11-16 |
2018-07-11 |
Sangamo Therapeutics, Inc. |
Modified dna-binding proteins and uses thereof
|
WO2013130824A1
(en)
|
2012-02-29 |
2013-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
AU2013259647B2
(en)
|
2012-05-07 |
2018-11-08 |
Corteva Agriscience Llc |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
EP2861737B1
(en)
|
2012-06-19 |
2019-04-17 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
DK2872625T3
(en)
|
2012-07-11 |
2017-02-06 |
Sangamo Biosciences Inc |
METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISEASES
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
JP6329537B2
(en)
|
2012-07-11 |
2018-05-23 |
サンガモ セラピューティクス, インコーポレイテッド |
Methods and compositions for delivery of biological agents
|
SI2890780T1
(en)
|
2012-08-29 |
2020-11-30 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
EP3750999B1
(en)
|
2012-09-04 |
2022-06-29 |
The Scripps Research Institute |
Chimeric polypeptides having targeted binding specificity
|
UA119135C2
(en)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Engineered transgene integration platform (etip) for gene targeting and trait stacking
|
AU2013312538B2
(en)
|
2012-09-07 |
2019-01-24 |
Corteva Agriscience Llc |
FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
UA118090C2
(en)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
EP2906684B8
(en)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
EP3789405A1
(en)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
JP2016500254A
(en)
|
2012-12-05 |
2016-01-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Methods and compositions for the regulation of metabolic diseases
|
BR112015013311A2
(en)
|
2012-12-07 |
2017-11-14 |
Haplomics Inc |
tolerance induction and factor 8 mutation repair
|
AU2014214719B2
(en)
|
2013-02-07 |
2020-02-13 |
The General Hospital Corporation |
Tale transcriptional activators
|
SG10201706741VA
(en)
|
2013-02-20 |
2017-10-30 |
Regeneron Pharma |
Genetic modification of rats
|
US10227610B2
(en)
|
2013-02-25 |
2019-03-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
CN105208866B
(en)
|
2013-03-21 |
2018-11-23 |
桑格摩生物治疗股份有限公司 |
Use engineering zinc finger protein nuclease targeted disruption T cell receptor gene
|
PT3456831T
(en)
|
2013-04-16 |
2021-09-10 |
Regeneron Pharma |
Targeted modification of rat genome
|
US10604771B2
(en)
|
2013-05-10 |
2020-03-31 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
CA2913404C
(en)
*
|
2013-06-14 |
2023-10-03 |
Cellectis |
Methods for non-transgenic genome editing in plants
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
AU2014312295C1
(en)
|
2013-08-28 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
US9957526B2
(en)
|
2013-10-17 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
JP6633532B2
(en)
|
2013-11-04 |
2020-01-22 |
ダウ アグロサイエンシィズ エルエルシー |
Optimal corn loci
|
CA2926822C
(en)
|
2013-11-04 |
2022-12-13 |
Dow Agrosciences Llc |
Optimal soybean loci
|
US9909131B2
(en)
|
2013-11-04 |
2018-03-06 |
Dow Agrosciences Llc |
Optimal soybean loci
|
US10093940B2
(en)
|
2013-11-04 |
2018-10-09 |
Dow Agrosciences Llc |
Optimal maize loci
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
NZ719477A
(en)
|
2013-11-11 |
2022-05-27 |
Sangamo Therapeutics Inc |
Methods and compositions for treating huntington’s disease
|
RS62559B1
(en)
|
2013-11-13 |
2021-12-31 |
Childrens Medical Center |
Nuclease-mediated regulation of gene expression
|
WO2015089077A2
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
HUE041331T2
(en)
|
2013-12-11 |
2019-05-28 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
KR102170502B1
(en)
|
2013-12-11 |
2020-10-28 |
리제너론 파마슈티칼스 인코포레이티드 |
Methods and compositions for the targeted modification of a genome
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
LT3102673T
(en)
|
2014-02-03 |
2020-08-25 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
KR102380324B1
(en)
|
2014-05-08 |
2022-03-30 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods and compositions for treating huntington's disease
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
WO2015188056A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
SG10201913804WA
(en)
|
2014-06-06 |
2020-03-30 |
Regeneron Pharma |
Methods and compositions for modifying a targeted locus
|
BR112016030145A8
(en)
|
2014-06-23 |
2018-12-11 |
Regeneron Pharma |
methods for assembling at least two nucleic acids and two or more nucleic acids
|
EP3161128B1
(en)
|
2014-06-26 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
EA039787B1
(en)
|
2014-07-14 |
2022-03-14 |
Вашингтон Стейт Юниверсити |
Livestock animal with ablation of germline cells and method of producing same
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
HUE055583T2
(en)
|
2014-09-16 |
2021-12-28 |
Sangamo Therapeutics Inc |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
RU2706965C2
(en)
|
2014-10-15 |
2019-11-21 |
Регенерон Фармасьютикалз, Инк. |
Methods and compositions for producing or maintaining pluripotent cells
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
JP6840077B2
(en)
|
2014-12-19 |
2021-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted gene modification through single-step multi-targeting
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
US20180094243A1
(en)
|
2015-04-03 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
BR112017024115A2
(en)
|
2015-05-12 |
2018-08-07 |
Sangamo Therapeutics Inc |
nuclease-mediated gene expression regulation
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
US10827730B2
(en)
|
2015-08-06 |
2020-11-10 |
The Curators Of The University Of Missouri |
Pathogen-resistant animals having modified CD163 genes
|
WO2017024343A1
(en)
|
2015-08-07 |
2017-02-16 |
Commonwealth Scientific And Industrial Research Organisation |
Method for producing an animal comprising a germline genetic modification
|
JP6853257B2
(en)
|
2015-09-23 |
2021-03-31 |
サンガモ セラピューティクス, インコーポレイテッド |
HTT repressor and its use
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
CN108473976B
(en)
|
2015-10-28 |
2022-07-19 |
桑格摩生物治疗股份有限公司 |
Liver-specific constructs, factor VIII expression cassettes, and methods of use thereof
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
WO2017091512A1
(en)
|
2015-11-23 |
2017-06-01 |
Sangamo Biosciences, Inc. |
Methods and compositions for engineering immunity
|
BR112018010503A2
(en)
|
2015-11-24 |
2018-11-13 |
Commw Scient Ind Res Org |
bird egg, method for replicating a virus, virus, method for producing a vaccine composition, vaccine composition, transgenic bird, and method for producing a bird
|
US11174466B2
(en)
|
2015-11-24 |
2021-11-16 |
Commonwealth Scientific And Industrial Research Organisation |
Production of viruses in cell culture
|
WO2017106537A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the mhc cell receptor
|
CN108778297B
(en)
|
2015-12-18 |
2024-02-09 |
桑格摩生物治疗股份有限公司 |
Targeted disruption of T cell receptors
|
US20170202931A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
CN109069568B
(en)
|
2016-02-02 |
2023-07-07 |
桑格摩生物治疗股份有限公司 |
Compositions for linking DNA binding domains and cleavage domains
|
EP3464323B1
(en)
|
2016-05-27 |
2021-09-22 |
Aadigen, LLC |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
ES2938210T3
(en)
|
2016-07-13 |
2023-04-05 |
Vertex Pharma |
Methods, compositions and kits to increase the efficiency of genome editing
|
ES2965134T3
(en)
|
2016-07-29 |
2024-04-11 |
Regeneron Pharma |
Mice containing mutations resulting in expression of C-truncated fibrillin-1
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
WO2018039448A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
LT3504229T
(en)
|
2016-08-24 |
2021-12-10 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
JP7256739B2
(en)
|
2016-09-07 |
2023-04-12 |
サンガモ セラピューティクス, インコーポレイテッド |
Modulation of liver genes
|
CN110050061A
(en)
|
2016-10-05 |
2019-07-23 |
富士胶片细胞动力公司 |
The mature pedigree of generation is induced multi-potent stem cell from what is destroyed with MeCP2
|
JP2019533676A
(en)
|
2016-10-13 |
2019-11-21 |
ジュノー セラピューティクス インコーポレイテッド |
Immunotherapy methods and compositions comprising tryptophan metabolic pathway modulators
|
GB2573062A
(en)
|
2016-10-14 |
2019-10-23 |
Harvard College |
AAV delivery of nucleobase editors
|
KR20190060829A
(en)
|
2016-10-20 |
2019-06-03 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods and compositions for the treatment of Fabry disease
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
KR20190085529A
(en)
|
2016-12-01 |
2019-07-18 |
상가모 테라퓨틱스, 인코포레이티드 |
Tau modulators and methods and compositions for their delivery
|
CN110494565A
(en)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
It is engineered B cell and compositions related and method
|
WO2018106782A1
(en)
|
2016-12-08 |
2018-06-14 |
Case Western Reserve University |
Methods and compositions for enhancing functional myelin production
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
BR112019014841A2
(en)
|
2017-01-23 |
2020-04-28 |
Regeneron Pharma |
guide rna, use of guide rna, antisense rna, sirna or shrna, use of antisense rna, sirna or shrna, isolated nucleic acid, vector, composition, cell, and, methods to modify an hsd17b13 gene in a cell, to decrease the expression of an hsd17b13 gene in a cell, to modify a cell and to treat an individual who does not carry the hsd17b13 variant
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
KR20190130613A
(en)
|
2017-03-23 |
2019-11-22 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Nucleobase edits comprising nucleic acid programmable DNA binding proteins
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
JP7297676B2
(en)
|
2017-04-28 |
2023-06-26 |
アクイタス セラピューティクス インコーポレイテッド |
Novel carbonyl lipids and lipid nanoparticle formulations for nucleic acid delivery
|
RU2019139045A
(en)
|
2017-05-03 |
2021-06-03 |
Сангамо Терапьютикс, Инк. |
METHODS AND COMPOSITIONS FOR MODIFICATION OF THE TRANSMEMBRANE CONDUCTIVITY REGULATOR GENE IN CYSTIC FIBROSIS (CFTR)
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
US10961537B2
(en)
|
2017-07-18 |
2021-03-30 |
Csl Behring Gene Therapy, Inc. |
Compositions and methods for treating beta-hemoglobinopathies
|
CN111801345A
(en)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE)
|
CN111511199A
(en)
|
2017-08-29 |
2020-08-07 |
科沃施种子欧洲股份两合公司 |
Improved blue paste and other separation system
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
ES2962277T3
(en)
|
2017-09-29 |
2024-03-18 |
Regeneron Pharma |
Rodents comprising a humanized Ttr locus and methods of use
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
CN111565730A
(en)
|
2017-11-09 |
2020-08-21 |
桑格摩生物治疗股份有限公司 |
Genetic modification of cytokine-induced SH2-containing protein (CISH) gene
|
EP3740479A1
(en)
|
2018-01-17 |
2020-11-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
WO2019143677A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
AU2019209293B2
(en)
|
2018-01-17 |
2023-07-27 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
WO2019157324A1
(en)
|
2018-02-08 |
2019-08-15 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
JP7338893B2
(en)
|
2018-03-20 |
2023-09-05 |
チンホワ ユニバーシティ |
Alzheimer's disease animal model and its use
|
KR20210020873A
(en)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Τ cells expressing recombinant receptors, related polynucleotides and methods
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
US11834686B2
(en)
|
2018-08-23 |
2023-12-05 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
US20210348177A1
(en)
|
2018-09-05 |
2021-11-11 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
JP2022500052A
(en)
|
2018-09-18 |
2022-01-04 |
サンガモ セラピューティクス, インコーポレイテッド |
Programmed cell death 1 (PD1) specific nuclease
|
US20220389395A1
(en)
|
2018-10-29 |
2022-12-08 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
WO2020112870A1
(en)
|
2018-11-28 |
2020-06-04 |
Forty Seven, Inc. |
Genetically modified hspcs resistant to ablation regime
|
MX2021007400A
(en)
|
2018-12-20 |
2021-07-15 |
Regeneron Pharma |
Nuclease-mediated repeat expansion.
|
EP3908568A1
(en)
|
2019-01-11 |
2021-11-17 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
US11857641B2
(en)
|
2019-02-06 |
2024-01-02 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type I
|
WO2020163017A1
(en)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Dna binding proteins and uses thereof
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
US20220170013A1
(en)
|
2019-03-06 |
2022-06-02 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
KR20210143230A
(en)
|
2019-03-19 |
2021-11-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Methods and compositions for editing nucleotide sequences
|
EP3946384A1
(en)
|
2019-04-02 |
2022-02-09 |
Sangamo Therapeutics, Inc. |
Methods for the treatment of beta-thalassemia
|
AU2020256225A1
(en)
|
2019-04-03 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
KR102487901B1
(en)
|
2019-04-04 |
2023-01-12 |
리제너론 파마슈티칼스 인코포레이티드 |
Methods for seamless introduction of targeted modifications into targeting vectors
|
WO2020206139A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
US20230165976A1
(en)
|
2019-04-10 |
2023-06-01 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
JP2022534867A
(en)
|
2019-06-04 |
2022-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Non-human animals containing humanized TTR loci with beta slip mutations and methods of use
|
SG11202111256XA
(en)
|
2019-06-07 |
2021-11-29 |
Regeneron Pharma |
Non-human animals comprising a humanized albumin locus
|
KR20220024053A
(en)
|
2019-06-14 |
2022-03-03 |
리제너론 파마슈티칼스 인코포레이티드 |
model of tauopathy
|
JP2022543112A
(en)
|
2019-08-01 |
2022-10-07 |
サナ バイオテクノロジー,インコーポレイテッド |
DUX4-expressing cells and their uses
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
CA3148370A1
(en)
|
2019-08-23 |
2021-03-04 |
Sana Biotechnology, Inc. |
Cd24 expressing cells and uses thereof
|
EP4051322A1
(en)
|
2019-11-01 |
2022-09-07 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
US20210130828A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
JP2022553573A
(en)
|
2019-11-08 |
2022-12-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
CRISPR and AAV strategies for X-linked juvenile retinal isolation therapy
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
JP2023515671A
(en)
|
2020-03-04 |
2023-04-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Methods and compositions for sensitizing tumor cells to immunotherapy
|
MX2022011831A
(en)
|
2020-03-25 |
2023-01-04 |
Sana Biotechnology Inc |
Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions.
|
EP4143315A1
(en)
|
2020-04-28 |
2023-03-08 |
The Broad Institute Inc. |
<smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene
|
JP2023525513A
(en)
|
2020-05-06 |
2023-06-16 |
セレクティス ソシエテ アノニム |
Methods for targeted insertion of exogenous sequences in the cellular genome
|
WO2021224416A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
CN116096873A
(en)
|
2020-05-08 |
2023-05-09 |
布罗德研究所股份有限公司 |
Methods and compositions for editing two strands of a target double-stranded nucleotide sequence simultaneously
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
KR20230042283A
(en)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
Engineered T cells conditionally expressing recombinant receptors, related polynucleotides and methods
|
CA3188664A1
(en)
|
2020-08-13 |
2022-02-17 |
Sonja SCHREPFER |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
KR20230090367A
(en)
|
2020-11-04 |
2023-06-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cells Expressing Chimeric Receptors from Modified Invariant CD3 Immunoglobulin Superfamily Chain Loci and Related Polynucleotides and Methods
|
US20240000051A1
(en)
|
2020-11-16 |
2024-01-04 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
WO2022146891A2
(en)
|
2020-12-31 |
2022-07-07 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating car-t activity
|
EP4263825A1
(en)
|
2021-02-19 |
2023-10-25 |
Beam Therapeutics, Inc. |
Recombinant rabies viruses for gene therapy
|
EP4313122A1
(en)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
WO2023287827A2
(en)
|
2021-07-14 |
2023-01-19 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023019203A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023023553A2
(en)
*
|
2021-08-17 |
2023-02-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems, and methods for activating and silencing gene expression
|
US20230270840A1
(en)
|
2021-09-08 |
2023-08-31 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023220043A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
WO2023220035A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|